Fonctions
Ingénieure de recherche IR2 CNRS
Equipe
Pathogénie mycobactérienne et nouvelles cibles thérapeutiques
Contact
email : francoise.roquet-baneres(at)irim.cnrs.fr
Tél : 04 34 35 94 47
Publications (5 dernières années)
2025
Isoniazid-Rhodanine molecular hybrids: Design, synthesis, antimycobacterial activity and computational validation. G. Kumar, S. Mishra, P. Seboletswe, N. Manhas, S. Ghumran, F. Roquet-Banères, L. Kremer, G. Bhargava, and P. Singh. 2025. RSC Adv. 15: 31272-31288.
Rationally designed InhA inhibitors: A comparative anti-tubercular activity study of sulfonate esters of isoniazid hydrazones and their structurally flexible benzyl analogues. M. G. Kadima, S. Mishra, G. Kumar, P. Seboletswe, F. Roquet-Banères, M. Foubert, L. Kremer, R. Karpoormath, and P. Singh. 2025. Chem. Biol. Drug Des. 106: e70171.
Rational design and antimycobacterial evaluation of aryl sulphonamide-linked isoniazid hydrazones against Mycobacterium tuberculosis. M. G. Kadima, S. Mishra, G. Kumar, P. Seboletswe, A. Kajee, Ankit, F. Roquet-Banères, M. Foubert, L. Kremer, R. Karpoormath, and P. Singh. 2025. ChemMedChem. 17: e202500398.
P3MA: A promising mycobacteriophage infecting Mycobacterium abscessus. A. Broncano-Lavado, J. J. Aguilera-Correa, F. Roquet-Banères, L. Kremer, A. Mediero, M. Seoane-Blanco, M. J. van Raaij, I. Pagán, J. Esteban, and M. García-Quintanilla. 2025. Antibiotics. 14: 801.
Genome Sequence of Mycobacterium abscessus phage P3MA. A. Broncano-Lavado, F. Roquet-Banères, L. Kremer, D. A. Russell, D. Jacobs-Sera, T. G. Reidy, J. J. Aguilera-Correa, J. Esteban, G. F. Hatfull and M. García-Quintanilla. 2025. Microbiol. Resour. Announc. 22: e0016925.
Isoniazid-dihydropyrimidinone molecular hybrids: Design, synthesis, antitubercular activity and cytotoxicity investigations with computational validation. G. Kumar, P. Seboletswe, S. Mishra, N. Manhas, S. Ghumran, N. Kerru, F. Roquet-Banères, M. Foubert, L. Kremer, G. Bhargava, P. Singh. 2025. ChemMedChem. 11: e2400949
SQ31f is a potent non-tuberculous mycobacteria antibiotic by targeting specifically the mycobacterial F-ATP synthase. P. Ragunathan, P. Sae-Lao, A. Harikishore, W. Daher, F. Roquet-Banères, L. Kremer, R. W. Bates, and G. Grüber. 2025. J. Antimicrob. Chemother. 80: 270-280.
2024
Design, synthesis, and anti-mycobacterial evaluation of Triclosan-Isoniazid hybrids. N. Gupta, S. Chowdhari, F. Roquet-Banères, L. Kremer, and V. Kumar. 2024. Chem. Biodiversity 13: e202401967.
Rational design and microwave-promoted synthesis of triclosan-based dimers: Targeting InhA for anti-mycobacterial profiling.
Shekhar, F. Roquet-Banères, A. Anand, L. Kremer, and V. Kumar. 2024. R. Soc. Open Sci. 11: 240676. DOI: 10.1098/rsos.240676.
Loss of LpqM proteins in Mycobacterium abscessus is associated with impaired intramacrophage survival.
Y.-M. Boudehen, W. Daher, F. Roquet-Baneres, and L. Kremer. 2024. mSpectrum. 12: e0383723. DOI: 10.1128/spectrum.03837-23.
2023
In vitro and in vivo efficacy of NITD-916 against Mycobacterium fortuitum.
F. Roquet-Banères, M. Alcaraz, C. Hamela, J. Abendroth, T. E. Edwards, and L. Kremer. 2023. Antimicrob. Agents Chemother. e01607-22.
2022
Efficacy and Mode of Action of a Direct Inhibitor of Mycobacterium abscessus InhA.
Alcaraz M, Roquet-Banères F, Leon-Icaza SA, Abendroth J, Boudehen YM, Cougoule C, Edwards TE, Kremer L. ACS Infect Dis. 2022 Oct 14;8(10):2171-2186. doi: 10.1021/acsinfecdis.2c00314. Epub 2022 Sep 15. PMID: 3610799
Designing quinoline-isoniazid hybrids as potent anti-tubercular agents inhibiting mycolic acid biosynthesis.
Alcaraz, B. Sharma, F. Roquet-Banères, C. Conde, T. Cochard, F. Biet, V. Kumar, and L. Kremer. 2022. Eur. J. Med. Chem. 239: 114531.
2021
Mycobacterium abscessus, un modèle de résistance aux différentes classes d’antibiotiques.
M. Illouz, M. Alcaraz, F. Roquet-Banères, and L. Kremer. 2021. Med. Sci. 37: 993-1001.
Mycobacteriophage-antibiotic therapy promotes enhanced clearance of drug-resistant Mycobacterium abscessus
D. Johansen, M. Alcaraz, R.M. Dedrick, F. Roquet-Banères, C. Hamela, G. F. Hatfull, and L. Kremer. 2021. Dis. Model. Mech. 14: dmm049159.
2020
Design and synthesis of 4-Aminoquinoline-isoindoline-dione-isoniazid triads as potential anti-mycobacterials.
Rani A, Johansen MD, Roquet-Banères F, Kremer L, Awolade P, Ebenezer O, Singh P, Sumanjit, Kumar V. Bioorg Med Chem Lett. 2020 Sep 24;30(22):127576. doi: 10.1016/j.bmcl.2020.127576.
Rifabutin is bactericidal against intracellular and extracellular forms of Mycobacterium abscessus.
Johansen MD, Daher W, Roquet-Banères F, Raynaud C, Alcaraz M, Maurer FP, Kremer L.Antimicrob Agents Chemother. 2020 Aug 17:AAC.00363-20. doi: 10.1128/AAC.00363-20.
Synergistic interactions of indole-2-carboxamides and β-lactam antibiotics against Mycobacterium abscessus.
Raynaud C, Daher W, Roquet-Banères F, Johansen MD, Stec J, Onajole OK, Ordway D, Kozikowski AP, Kremer L.
Antimicrob Agents Chemother 2020 Feb 10. pii: AAC.02548-19. doi: 10.1128/AAC.02548-19.
Active Benzimidazole Derivatives Targeting the MmpL3 Transporter in Mycobacterium abscessus.
Raynaud C, Daher W, Johansen MD, Roquet-Banères F, Blaise M, Onajole OK, Kozikowski AP, Herrmann JL, Dziadek J, Gobis K, Kremer L.
ACS infectious diseases ACS Infect Dis 2020 Jan 7. doi: 10.1021/acsinfecdis.9b00389.